Limited β₂-adrenoceptor haplotypes display different agonist mediated airway responses in asthmatics

• Main Authors: Hart Guus AM, Weller Frank R, Westland Robert, Wierenga Eddy A, van Veen Anneke, Jansen Henk M, Jonkers René E
• Format: Article
• Language: English
• Published: BMC 2006-01-01
• Series: Respiratory Research
• Online Access: http://respiratory-research.com/content/7/1/19

<p>Abstract</p> <p>Background</p> <p><it>In vitro </it>and some <it>in vivo </it>studies suggested that genetic haplotypes may have an impact on β₂-agonist mediated airway responses in asthmatics. Due to strong linkage disequilibrium the single nucleotide polymorphisms (SNPs) in the β₂-adrenoceptor gene result in only a limited number of haplotypes. We intended to evaluate the impact of β₂-adrenoceptor haplotypes on β₂-agonist mediated airway responses and the development of tolerance in mild to moderate asthmatics.</p> <p>Methods</p> <p>Patients were genotyped for the part of the β₂-adrenoceptor gene with a known bearing on receptor function and regulation. Cumulative dose response curves of fenoterol versus PD₂₀methacholine and FEV₁were constructed after 2 week treatment periods with either terbutaline or placebo in a double blind, randomised and cross-over design. Analysis of the dose response curves was based on a repeated measurement analysis of covariance.</p> <p>Results</p> <p>In our study population comprising 45 asthmatic patients, we found three limited allelic haplotypes, resulting in six different genotypes. Our data support the existence of differences between these six genotypes both in the shape of the dose response relationship of the β₂-adrenoceptor agonist fenoterol as well as in the propensity to develop tolerance for these effects by pre-treatment with terbutaline. However, this could only be substantiated for the endpoint PD₂₀methacholine.</p> <p>Conclusion</p> <p>Between β₂-adrenoceptor genotypes differences exist both in baseline β₂-agonist induced airway responses as well as in the propensity to develop tolerance during maintenance β₂-agonist therapy. The net differences after two weeks of therapy are, however, of magnitudes that are unlikely to be of clinical significance.</p>